The in vivo visualization of hormone-dependent tumor growth was essential for the development of anti-estrogen drugs, eventually leading to the production and optimization of Fulvestrant, the first selective ER down-regulator (SERD) currently used as standard-of-care for HR+ BCs patients [218–220]. This evidence concerns the gene ESR1 and neoplasm.